EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. EntreMed’s drug candidates target disease cells and the blood vessels that nourish them. The Company’s goal is to develop and commercialize therapeutic products based on its scientific expertise in angiogenesis, cell cycle regulation, cell signaling, and inflammation – processes that are vital to the progression of cancer and other diseases.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 01/01/12 | Other | 10M | Unknown |
News
5AM Ventures closes $119M for third life science fund
March 23, 2009 4:54 pm
5AM Ventures , a Menlo Park, Calif. venture firm specializing in seed or early-stage life science and biopharmaceutical investments, announced… Continue reading ⟩